Yuko Nakayama
Overview
Explore the profile of Yuko Nakayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
1236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ozawa T, Shoda K, Kawaguchi Y, Akaike H, Maruyama S, Takiguchi K, et al.
Gan To Kagaku Ryoho
. 2024 Feb;
50(13):1633-1635.
PMID: 38303365
An 81-year-old man with advanced esophagogastric junction cancer with paraaortic lymph node metastasis was treated with S-1 plus oxaliplatin and nivolumab combination chemotherapy. Subsequently, conversion surgery was performed, and the...
12.
Sakuramachi M, Murakami N, Nagao A, Kojima K, Miyata Y, Kashihara T, et al.
J Contemp Brachytherapy
. 2024 Jan;
15(6):465-469.
PMID: 38230404
Purpose: The use of a hydrogel spacer inserted into recto-vaginal fossa is a valuable strategy to mitigate radiation exposure to the rectum during radiation therapy for female pelvic malignancies. However,...
13.
Nakahara M, Murakami N, Chiba T, Nagao A, Okuma K, Kashihara T, et al.
Brachytherapy
. 2023 Dec;
23(1):45-51.
PMID: 38040606
Background: Despite its efficacy, if adherence to dose constraints for surrounding normal tissues proves unattainable, the risk of late radiation-related adverse events after primary radiotherapy involving brachytherapy remains a noteworthy...
14.
Igaki H, Nakamura S, Yamazaki N, Kaneda T, Takemori M, Kashihara T, et al.
Front Oncol
. 2023 Oct;
13:1272507.
PMID: 37901311
This study reports the first patient treatment for cutaneous malignant melanoma using a linear accelerator-based boron neutron capture therapy (BNCT) system. A single-center open-label phase I clinical trial had been...
15.
Nakayama Y, Enomoto D, Yamamoto K, Takara K
Anticancer Res
. 2023 Sep;
43(10):4349-4357.
PMID: 37772579
Background/aim: Mammalian target of rapamycin (mTOR) inhibitors represent the standard of care for metastatic renal cell carcinoma (RCC). However, treatment outcomes are relatively poor, suggesting a potential problem with tolerating...
16.
Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M, et al.
Radiother Oncol
. 2023 Jan;
180:109454.
PMID: 36640944
Introduction: Concurrent chemoradiotherapy (CCRT) has been the standard of care for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Background And Purpose: The results of the PACIFIC trial established...
17.
Miyata Y, Murakami N, Okuma K, Nakayama Y, Itami J, Natsume T, et al.
Adv Radiat Oncol
. 2022 Nov;
8(1):101118.
PMID: 36438436
No abstract available.
18.
Kashihara T, Ogata D, Okuma K, Nakamura S, Nakayama H, Mori T, et al.
Skin Res Technol
. 2022 Nov;
29(1):e13243.
PMID: 36404577
Introduction: Scalp angiosarcoma is a rare and aggressive cancer. Definitive radiotherapy is a treatment option for localised scalp angiosarcoma patients. Although definitive surgical resection reportedly prolongs overall survival (OS), whether...
19.
Noda-Narita S, Naito T, Udagawa H, Goto K, Miyawaki T, Mamesaya N, et al.
Cancer Sci
. 2022 Oct;
114(2):630-639.
PMID: 36285515
The role of previous thoracic radiation therapy as a risk factor of immune-related pneumonitis is unclear. Furthermore, some patients develop radiation recall pneumonitis, which is characterized by a radiation pneumonitis-like...
20.
Miyata Y, Murakami N, Honma Y, Mori T, Yoshimoto S, Kashihara T, et al.
J Radiat Res
. 2022 Sep;
63(6):879-883.
PMID: 36149017
Sinonasal undifferentiated carcinoma (SNUC) is a highly aggressive and uncommon neoplasm that arises from the mucosa of the nasal cavity or paranasal sinuses. The multidisciplinary approach that includes surgery, radiation...